Salivary Gland Cancer
Salivary gland cancers are rare and histologically diverse — including mucoepidermoid, adenoid cystic, and salivary duct carcinomas — requiring expert pathologic review to guide management. Androgen receptor positivity in salivary duct carcinoma and NTRK fusions in certain subtypes open targeted therapy opportunities. CancerFax helps patients access specialist head and neck oncology review, molecular testing, and advanced systemic options for rare salivary tumors.
- Histologic subtype, AR status & NTRK/HER2 profiling
- AR-targeted therapy, TRK inhibitors & specialist surgery
- Rare salivary cancer specialist & trial access
- Incidence
- ~3–5% of head and neck malignancies; rare overall
- Most Common Gland
- Parotid (~70–80% of all salivary gland tumors)
- Key Diagnostic Test
- Core needle biopsy + IHC + molecular/NGS panel
- Key Biomarkers
- HER2, NTRK fusions, MYB-NFIB, AR, CRTC1-MAML2
- Advanced Therapies
- Trastuzumab, T-DXd, Larotrectinib, Lenvatinib, Nivolumab (Trials)
What is Salivary Gland Cancer
Types and Subtypes of Salivary Gland Cancer
Salivary gland carcinomas are classified primarily by histologic subtype, with grade providing additional prognostic stratification for several types. The most common and clinically significant malignant subtypes are described below, along with their molecular hallmarks and key management implications.
Symptoms and Signs of Salivary Gland Cancer
Salivary gland cancers often present as a painless or minimally symptomatic mass overlying the parotid, submandibular, or sublingual gland regions, or as a submucosal swelling within the oral cavity. Several clinical features that distinguish malignant from benign salivary gland tumors should trigger urgent evaluation, particularly facial nerve involvement and rapid growth.
Causes and Risk Factors
Most salivary gland cancers arise sporadically without a clear identifiable cause. Several risk factors have been associated with increased incidence, though the evidence for many is based on limited data given the rarity of these tumors. Molecular drivers are well-characterized for specific subtypes and are more clinically relevant than traditional risk factors for treatment planning.
Diagnosis and Investigations
Salivary gland cancer is diagnosed using the tissue usually collected through FNAC or CNB performed under ultrasound guidance. As the salivary gland tumors have a highly heterogeneous histology, evaluation by a specialist in head and neck pathology is recommended. With molecular testing becoming increasingly necessary for subtype identification and treatment planning in advanced cases, pathological review is imperative.
Staging and Risk Groups
The classification of salivary gland carcinomas is done according to the TNM staging system of the AJCC, 8th Edition. The "T" in TNM denotes the size of the primary tumor along with the degree of its local invasion, "N" is associated with regional lymph node spread, and "M" relates to distant metastasis. However, it is important to note that histologic grade and type play as much importance, if not more, as TNM stage in the management of stage I salivary duct carcinoma.
Standard Treatment Options
Salivary gland carcinoma is managed according to its subtypes and stages. Surgery is the main mode of treatment in all operable cases, with radiation being used in almost all patients as a form of adjuvant treatment due to certain risk factors. In advanced cases, systemic treatment can be initiated depending on the subtype with better results if molecular findings are known beforehand.
Advanced and Emerging Therapies
A change in paradigm from empiric chemotherapy treatment to molecular-targeted and immunotherapy treatment of salivary gland carcinoma has occurred. The most important thing for achieving this modality of treatment is the precise histopathological typing together with molecular characterization.
Targeted Therapy
Trastuzumab + Pertuzumab + Docetaxel (HER2-Positive SDC)
For HER2-amplified or HER2-overexpressing salivary duct carcinoma, the combination of dual HER2 blockade (trastuzumab + pertuzumab) plus docetaxel has demonstrated response rates of 50–70% and is considered the standard first-line regimen. This mirrors the established breast cancer HER2-positive protocol and is supported by multiple prospective studies in SDC.
Targeted Therapy
Trastuzumab Deruxtecan (T-DXd) — HER2-Positive Salivary Gland
T-DXd (HER2-directed antibody-drug conjugate) has demonstrated clinical activity in HER2-positive salivary gland carcinoma including salivary duct carcinoma. It is being evaluated as first- and subsequent-line therapy. CancerFax can support access evaluation for patients with HER2-positive disease who have progressed on prior HER2-directed therapy.
Targeted Therapy
Larotrectinib / Entrectinib (NTRK Fusion-Positive — Secretory Carcinoma)
NTRK inhibitors are approved in a tumor-agnostic context for NTRK fusion-positive malignancies. ETV6-NTRK3-positive secretory carcinoma is highly sensitive to larotrectinib and entrectinib, with high response rates and durable remissions. NTRK testing should be performed for all secretory carcinoma diagnoses and for salivary gland carcinomas where the subtype diagnosis is uncertain.
Targeted Therapy
Combined Androgen Blockade (AR-Positive, HER2-Negative SDC)
For AR-positive salivary duct carcinoma without HER2 amplification, combined androgen blockade (bicalutamide + LHRH agonist, or enzalutamide) provides disease stabilization in a substantial proportion of patients. This approach is particularly relevant in patients unsuitable for chemotherapy. AR status should be assessed in all SDC cases.
Targeted Therapy
Lenvatinib / Axitinib / Sunitinib (Adenoid Cystic Carcinoma)
Anti-angiogenic multi-TKIs have demonstrated disease stabilization and modest objective response rates in recurrent/metastatic adenoid cystic carcinoma — a subtype characterized by high VEGFR/FGFR signaling. Lenvatinib and axitinib are the most studied. These agents are used when symptomatic progression requires systemic intervention for ACC, where chemotherapy is typically less active.
Radiation
Proton Beam Radiation / Carbon Ion Therapy
Proton beam radiation and carbon ion therapy offer physical dose distribution advantages over conventional photon RT, particularly for skull base and deep parotid tumors adjacent to critical structures including the brainstem, optic apparatus, and cochlea. Carbon ion therapy has demonstrated promising local control rates in adenoid cystic carcinoma in European and Japanese studies. Available at specialist proton and heavy ion centers.
Immunotherapy
Nivolumab / Pembrolizumab (Checkpoint Inhibitors — Selected Subtypes)
PD-1/PD-L1 checkpoint inhibitors have modest overall activity in unselected salivary gland carcinoma but have shown more consistent activity in EBV-associated lymphoepithelial carcinoma and TMB-high / dMMR tumors. Multiple clinical trials are evaluating checkpoint inhibitors in salivary gland carcinoma — including combinations with anti-VEGF agents for ACC and with HER2-directed therapy for SDC.
Targeted Therapy
NF1 / RAS / MEK-Targeted Therapy (Molecularly Selected)
NF1 loss and RAS pathway activation have been identified in a subset of salivary gland carcinomas. MEK inhibitors and other RAS-MAPK pathway inhibitors are being explored in molecularly selected patients through basket trial programs. Comprehensive NGS profiling at recurrence identifies patients potentially eligible for these approaches.
Biomarkers and Precision Medicine in Salivary Gland Cancer
Molecular biomarkers are central to the management of salivary gland carcinoma, they are diagnostic, prognostic, and increasingly predictive of targeted therapy response. The actionable landscape is subtype-specific. Comprehensive profiling at diagnosis of advanced disease is essential to identify all relevant therapeutic targets and trial eligibility.
When to Seek a Second Opinion
Salivary gland cancers are among the rarest and most histologically complex malignancies in head and neck oncology. Correct subtype classification, surgical planning, and systemic therapy selection require specialist expertise that is concentrated at high-volume head and neck oncology centers. Second opinions are appropriate in several common scenarios:
Clinical Trials and Research in Salivary Gland Cancer
Prognosis and Key Outcome Factors
The prognosis of salivary gland carcinoma depends heavily on the type of carcinoma and must be looked at in terms of its grade of malignancy, staging, site, and whether there are therapeutic molecular targets. Low-grade carcinomas, such as acinic cell, secretory, and low-grade MEC, have excellent prognoses when treated with surgery and radiotherapy. High-grade carcinomas, like salivary duct carcinoma, high-grade MEC, and carcinoma ex pleomorphic adenoma, have a high chance of metastasizing and require a more aggressive treatment method. Adenoid cystic carcinoma is different from other types of salivary gland cancer because although not likely to be cured after it recurs, the tumor has a rather slow course and can have a good prognosis even with metastasis.
Supportive Care and Living With Salivary Gland Cancer
Salivary gland cancer treatment has significant functional consequences depending on the primary site, surgical extent, and use of radiation. Comprehensive supportive care addressing these dimensions is fundamental to quality of life during and after treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax supports patients with salivary gland cancer in accessing specialist head and neck oncology review, second opinions on subtype classification and surgical planning, HER2 and NTRK targeted therapy eligibility assessment, and identification of clinical trials and advanced therapy options — including at specialist centers in China and internationally for cross-border care.
Get a free case reviewFrequently Asked Questions About Salivary Gland Cancer
Salivary gland cancer is a malignancy arising from the salivary glands — either the three major pairs (parotid, submandibular, sublingual) or the hundreds of minor salivary glands distributed throughout the oral cavity, oropharynx, larynx, and paranasal sinuses. The parotid gland is the most commonly affected major gland, accounting for approximately 70–80% of salivary gland tumors overall, though most parotid tumors are benign. The proportion of malignant tumors is higher in the submandibular and minor salivary glands. Salivary gland carcinomas account for approximately 3–5% of all head and neck cancers and are considered rare malignancies.
The most common presentation is a painless or mildly tender lump or swelling in front of the ear (parotid), beneath the jaw (submandibular), or in the floor of the mouth or palate (minor salivary glands). Many salivary gland tumors grow slowly and are initially assumed to be benign. Clinical features that increase the suspicion for malignancy include: facial weakness or paralysis (indicating facial nerve involvement by a parotid mass), rapid growth, fixation of the mass to overlying skin or underlying structures, skin dimpling, and associated neck lymphadenopathy. Any persistent salivary gland swelling that does not resolve should be evaluated with ultrasound and, if indicated, biopsy.
Mucoepidermoid carcinoma is the most common type and ranges from low-grade (excellent prognosis with surgery) to high-grade (aggressive, requiring multimodal treatment). Adenoid cystic carcinoma (ACC) is the second most common and is known for perineural spread and very late distant relapse — often decades after initial treatment; it follows an indolent but persistent course. Salivary duct carcinoma is an aggressive, high-grade tumor that frequently overexpresses HER2 and androgen receptor, enabling targeted therapy. Secretory carcinoma (formerly MASC) harbors an ETV6-NTRK3 fusion and is highly sensitive to NTRK inhibitors. Acinic cell carcinoma is generally low-grade with a favorable outlook. Each subtype requires a distinct management approach.
Surgery is the primary treatment for all localized, resectable salivary gland carcinomas and remains the cornerstone of management. For parotid carcinomas, superficial or total parotidectomy with facial nerve preservation (when oncologically feasible) is the standard operation. Minor salivary gland tumors are managed by wide local excision of the primary site. In unresectable or metastatic disease, the goal of treatment shifts to systemic therapy — with targeted agents (HER2-directed, NTRK inhibitors, AR-targeted) or chemotherapy depending on subtype and molecular profile. Adenoid cystic carcinoma with stable, asymptomatic metastases may be managed with surveillance before initiating systemic therapy, reflecting its indolent natural history.
The facial nerve (cranial nerve VII) runs through the parotid gland and controls all muscles of facial expression. Facial nerve preservation is the primary technical objective of parotid surgery for cancer — the nerve is identified and carefully dissected free of the tumor when it is not directly invaded. When the facial nerve is encased by or adherent to the tumor and cannot be preserved without leaving positive margins, it must be sacrificed, resulting in ipsilateral facial paralysis. In such cases, immediate nerve grafting (using the sural nerve from the leg, or other donor nerves) may partially restore facial movement over time. The decision regarding facial nerve management requires specialist parotid cancer surgical expertise.
Yes — HER2 testing is critical for salivary duct carcinoma and high-grade salivary gland adenocarcinoma. HER2 amplification or overexpression occurs in approximately 30–40% of SDC cases and defines eligibility for highly active HER2-directed regimens including trastuzumab + pertuzumab + docetaxel and, more recently, trastuzumab deruxtecan (T-DXd). Without HER2 testing, patients with HER2-positive SDC may be treated with standard chemotherapy when a more effective targeted option is available. HER2 IHC and FISH should be performed at diagnosis in all salivary duct carcinomas and high-grade salivary gland adenocarcinomas before initiating systemic therapy.
Adenoid cystic carcinoma (ACC) is biologically distinct from other salivary gland carcinomas in several important ways. It is characterized by perineural spread along cranial nerves, which drives local recurrence along nerve pathways even after apparently adequate surgery. It has a propensity for late distant metastasis to the lungs, bone, and liver — often appearing 10–15 years after initial treatment. Metastatic ACC frequently follows an indolent course, with patients surviving for years with stable disease before requiring systemic intervention. Standard chemotherapy has limited activity in ACC. Anti-angiogenic agents (lenvatinib, axitinib) are the most commonly used systemic therapies for progressive metastatic disease, and novel MYB-targeted and FGFR-targeted approaches are in clinical development.
At minimum, salivary duct carcinoma should undergo HER2 testing (IHC + FISH) and androgen receptor (AR) IHC. All secretory carcinoma diagnoses should be confirmed with ETV6-NTRK3 FISH or RT-PCR (or pan-TRK IHC screening). Suspected adenoid cystic carcinoma should have MYB-NFIB FISH or MYB IHC. For advanced, recurrent, or metastatic salivary gland carcinoma of any subtype, comprehensive NGS-based molecular profiling (DNA + RNA) is recommended to assess PD-L1, TMB, MSI/dMMR, FGFR, RET, ALK, and other actionable alterations. CancerFax can assist in coordinating comprehensive molecular testing at specialist centers where it is not available locally.
Yes. Despite the rarity of the disease, several active clinical trials are enrolling patients with specific salivary gland carcinoma subtypes. HER2-positive salivary gland carcinoma trials include T-DXd studies and HER2-directed combination immunotherapy trials. Adenoid cystic carcinoma trials include lenvatinib/immunotherapy combinations, FGFR inhibitor studies, and MYB-targeting approaches. Basket trials for NTRK, RET, and FGFR fusions enroll salivary gland carcinoma patients alongside other solid tumors. Checkpoint inhibitor trials are enrolling patients with EBV-associated, TMB-high, or PD-L1-positive disease. CancerFax can help identify appropriate open trials at specialist centers in China, the United States, Europe, and Japan, matched to your molecular profile and prior treatment history.
Yes. CancerFax supports patients with salivary gland cancer throughout the treatment journey. Our services include specialist head and neck oncology review, second opinions on pathologic subtype classification and surgical planning, coordination of HER2, AR, NTRK, and comprehensive NGS molecular profiling, and identification of targeted therapy and clinical trial opportunities. For patients with salivary duct carcinoma, secretory carcinoma, or adenoid cystic carcinoma, CancerFax helps access subtype-appropriate targeted therapies — including options at specialist centers in China, Japan, and globally. We also support cross-border treatment logistics for patients seeking specialist care internationally. Share your medical reports with the CancerFax team to begin.